Last checked at LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:
----------
FTSE 100
----------
GOLDMAN STARTS VODAFONE WITH 'BUY' - PRICE TARGET 275 PENCE
----------
MORGAN STANLEY RAISES ASTRAZENECA PRICE TARGET TO 3800 (3700) PENCE - 'EQUAL-WEIGHT'
----------
MORGAN STANLEY RAISES AVIVA PRICE TARGET TO 517 (514) PENCE - 'OVERWEIGHT'
----------
SOCGEN CUTS SMITH & NEPHEW PRICE TARGET TO 630 (660) PENCE
----------
PANMURE CUTS G4S TO 'SELL' ('HOLD') - TARGET 200 (275) PENCE
----------
GOLDMAN CUTS TULLOW OIL PRICE TARGET TO 1,080 (1,125) PENCE - 'BUY'
----------
NOMURA RAISES TUI TRAVEL PRICE TARGET TO 440 (310) PENCE - 'NEUTRAL'
----------
HSBC RAISES PETROFAC TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 1,400 (1,225) PENCE
----------
GOLDMAN CUTS ADMIRAL GROUP TO 'NEUTRAL' ('BUY')
----------
FTSE 250
----------
BARCLAYS RAISES PACE TO 'OVERWEIGHT' ('EQUAL WEIGHT') - TARGET 450 (320) PENCE
----------
GOLDMAN CUTS REDROW TO 'NEUTRAL' ('BUY')
----------
DEUTSCHE BANK INITIATES RPC GROUP WITH 'BUY' - TARGET 670 PENCE
----------
UBS CUTS PREMIER OIL TO 'NEUTRAL' ('BUY') - TARGET 315 (350) PENCE
----------
GOLDMAN CUTS ITE GROUP PRICE TARGET TO 380 (400) PENCE - 'BUY'
----------
UBS CUTS INCHCAPE PRICE TARGET TO 605 (615) PENCE - 'NEUTRAL'
----------
NOMURA CUTS INCHCAPE PRICE TARGET TO 580 (600) PENCE - 'NEUTRAL'
----------
HSBC RAISES AFRICAN BARRICK GOLD TO 'NEUTRAL' ('UW') - TARGET 230 (160) PENCE
----------
HSBC RAISES HIKMA PHARMACEUTICALS TARGET TO 1,300 (1,035) PENCE - 'NEUTRAL'
----------
NUMIS RAISES CATLIN PRICE TARGET TO 570 (560) PENCE - 'HOLD'
----------
ALL-SHARE AND AIM
----------
JEFFERIES CUTS APR ENERGY PRICE TARGET TO 1,250 (1,260) PENCE - 'BUY'
----------
NUMIS CUTS HYDER CONSULTING TO 'HOLD' ('BUY') - TARGET 585 (760) PENCE
----------
LIBERUM CUTS HYDER CONSULTING TO 'HOLD' ('BUY') - TARGET 520 (630) PENCE
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.
3 Jan 2023 09:25
Hikma launches version of Xyrem medicine in US for treating narcolepsy
(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.
Read more
